SQI Diagnostics Announces First SQiDworks(TM) Platform Shipped for Validation Trials



    - Mount Sinai Hospital will test rheumatoid arthritis panel on SQI
    Diagnostics' automated platform -

    TORONTO, Jan. 8 /CNW/ - SQI Diagnostics Inc. (TSX-Venture: SQD), a
medical systems automation company focused on evolving laboratory-based
biomarker testing, today announced that it has shipped the first SQiDworks(TM)
platform and accompanying QuantiSpot(TM) microarray consumables to Mount Sinai
Hospital, which operates a globally recognized autoimmune reference laboratory
in Toronto. Mount Sinai will begin validation trials evaluating the analytic
performance of the SQiDworks/QuantiSpot system in diagnosing rheumatoid
arthritis using its panel of commonly assayed biomarkers.
    "Shipping our first workstation and QuantiSpot microarray consumables to
Mount Sinai Hospital offers the first opportunity to showcase the ease-of-use,
speed, and accuracy of our technology in an active laboratory setting. The
data generated in this external validation trial will be used in our FDA
submission and bring us closer to commercialization of our proprietary
biomarker testing technology," said Claude Ricks, CEO of SQI Diagnostics. "Our
system should enable Mount Sinai to complete more rheumatoid arthritis tests
at a faster rate with lower cost and with specificity and sensitivity equal to
or better than current assays."
    SQI Diagnostics' internal validation trials demonstrate that its
rheumatoid arthritis microassay panel correlated well with current industry
standard ELISA tests and showed wider dynamic assay ranges. The microarray
includes in-array calibration and the four commonly prescribed biomarkers to
diagnose rheumatoid arthritis, specifically Rheumatoid Factor IgA, IgM, IgG,
and anti CCP IgG. SQI Diagnostics' trial focused on its proprietary novel
capture molecule for CCP and determined that its CCP biomarker has sensitivity
and specificity that is equal to the leading assays.
    "Early detection and regular monitoring could significantly improve the
management of rheumatoid arthritis which affects approximately 1% of the
general population in the US," said Mount Sinai Representative Dr. Kenneth
Pritzker, Director, Pathology and Laboratory Medicine, Mount Sinai Hospital.
"Our current technology requires our lab to complete four separate tests in a
semi-automatic fashion for every patient sample. With SQiDworks automation and
QuantiSpot multiplexed assay we have the opportunity to deliver the same
clinical results in one test per patient and with significant savings in lab
technician labour and reagent consumption."
    SQI Diagnostics expects to ship additional platforms and its
corresponding microarray consumables to leading US centers for further
validation trials in Q1 2008. The data collected from these studies, together
with internal trial data, will be used in SQI Diagnostics' 510(k) application
to the Food and Drug Administration in the first half of 2008.

    About SQiDworks(TM)

    SQiDworks(TM) is a fully-automated fluidics workstation, scanner and
analytical device used to process SQI Diagnostics proprietary QuantiSpot
microarray test devices. The platform fully integrates all assay steps for
hands-free work-flow and is compatible with standard lab automation systems.
The platform is capable of processing up to 240 patient samples per run and
when combined with the Company's QuantiSpot multiplexed tests can produce
quantified determinations for up to 960 individual test results per hour
resulting in significant laboratory efficiencies and cost-savings.

    About QuantiSpot(TM)

    The SQI Diagnostics microarray device, QuantiSpot(TM), is a multiplexed
assay consumable for use with the SQiDworks workstation. QuantiSpot tests are
currently being developed for the detection and quantification of biomarkers
used in the diagnosis of Autoimmune Disease, Infectious Disease and Allergic
conditions, among others. Each of the 96 wells of the QuantiSpot device
contains proprietary microarrays for duplicate antibody capture, in-sample
calibration and redundant test controls. When combined with the SQiDworks
fully-automated workstation users are able to process multiplexed assays to
quantify serum concentrations of up to 12 individual biomarkers or the
qualitative detection of up to 24 biomarkers per patient.

    About SQI Diagnostics

    SQI Diagnostics is a medical systems automation company focused on
evolving laboratory-based biomarker testing. Using automation and proprietary
miniaturization technologies, SQI Diagnostics significantly improves the
economies of scale for laboratories performing multiple biomarker testing at
high volumes, allowing them to deliver patient results faster using less labor
and fewer resources. SQI Diagnostics' platform has a user-friendly interface,
100% quality control, high sample throughput and offers a more efficient
alternative to current testing options. SQI Diagnostics' initial products
target the $1.4 billion autoimmune disease market, with initial products for
Rheumatoid Arthritis and Thrombosis scheduled for launch in 2007. SQI
Diagnostics is based in Toronto, Canada. For further information please visit
www.sqidiagnostics.com.

    Certain information in this press release is based on beliefs and
assumptions of the Company's senior management and information currently
available to it that may constitute forward-looking information within the
meaning of securities laws. Such statements reflect the current views of the
Company with respect to future events and are subject to certain risks and
uncertainties. Actual results, events, and performance may differ materially.
Readers are cautioned not to place undue reliance on these forward-looking
statements.

    This release was prepared by management of the Company who takes full
responsibility for its contents. The TSX Venture Exchange has not reviewed and
does not accept responsibility for the adequacy or accuracy of this news
release.

    %SEDAR: 00021000E




For further information:

For further information: Chief Financial Officer, Andrew Morris, (416)
674-9500 ext. 229, amorris@sqidiagnostics.com; Investor Relations, James
Smith, (416) 815-0700 ext. 229, jsmith@equicomgroup.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890